Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Blankenfelde-Mahlow – page 29

1 867 clinical trials in Blankenfelde-Mahlow, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Blankenfelde-Mahlow at a glance
1 867
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 867 trials in Blankenfelde-Mahlow

Open in trial search

Study of enfortumab vedotin and avelumab for patients with advanced or metastatic penile cancer that has spread or cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:Queen Mary University Of London

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT326
  • Sponsor:BioNTech SE

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative+1

Recruiting

Study of MT-501 in patients with active Crohn's Disease or Ulcerative Colitis: A Phase 2 safety and effectiveness trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MT-201
  • Sponsor:Mirador Therapeutics Inc.

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Blankenfelde-Mahlow

What the registry says about research in the country

01 Psoriasis Research

Comprehensive studies evaluating new therapeutic approaches for moderate to severe plaque psoriasis, including multiple clinical trials testing novel treatments and comparing their effectiveness to existing options.

  • Treatment evaluation studies
  • Long-term safety assessments
  • Comparative efficacy research

Multiple promising compounds being investigated to expand treatment options for patients with persistent symptoms.

02 Atopic Dermatitis Studies

Innovative research focusing on moderate to severe atopic dermatitis, investigating both standalone treatments and combination therapies with topical corticosteroids.

  • Novel biological therapies
  • Dose optimization studies
  • Adolescent and adult treatments

Emphasis on developing solutions for patients who haven't responded well to conventional treatments.

03 Specialized Dermatological Conditions

Research encompassing various skin conditions including chronic hand eczema, vitiligo, and hidradenitis suppurativa.

  • Targeted therapies
  • Novel treatment approaches
  • Long-term management strategies

Focus on developing effective treatments for conditions that significantly impact quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.